

Accepted Manuscript

Efficacy and Safety of Sofosbuvir plus Daclatasvir for Treatment of HCV-associated Cryoglobulinemia Vasculitis

David Saadoun, Stanislas Pol, Yasmina Ferfar, Laurent Alric, Christophe Hezode, Si Nafa Si Ahmed, Luc de Saint Martin, Cloé Comarmond, Anne Sophie Bouyer, Lucile Musset, Thierry Poynard, Matthieu Resche Rigon, Patrice Cacoub

PII: S0016-5085(17)30269-X
DOI: [10.1053/j.gastro.2017.03.006](https://doi.org/10.1053/j.gastro.2017.03.006)
Reference: YGAST 61038

To appear in: *Gastroenterology*
Accepted Date: 3 March 2017

Please cite this article as: Saadoun D, Pol S, Ferfar Y, Alric L, Hezode C, Si Ahmed SN, de Saint Martin L, Comarmond C, Bouyer AS, Musset L, Poynard T, Resche Rigon M, Cacoub P, Efficacy and Safety of Sofosbuvir plus Daclatasvir for Treatment of HCV-associated Cryoglobulinemia Vasculitis, *Gastroenterology* (2017), doi: 10.1053/j.gastro.2017.03.006.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Efficacy and Safety of Sofosbuvir plus Daclatasvir for Treatment of HCV-associated Cryoglobulinemia Vasculitis

David Saadoun^{1,2,3,4}, Stanislas Pol⁵, Yasmina Ferfar^{1,2,3,4}, Laurent Alric⁶, Christophe Hezode⁷, Si Nafa Si Ahmed⁸, Luc de Saint Martin⁹, Cloé Comarmond^{1,2,3,4}, Anne Sophie Bouyer^{1,2,3,4}, Lucile Musset¹⁰, Thierry Poynard¹¹, Matthieu Resche Rigon¹², Patrice Cacoub^{1,2,3,4}

¹ Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; ² INSERM, UMR_S 959, F-75013, Paris, France; ³ CNRS, FRE3632, F-75005, Paris, France; ⁴ AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France; ⁵ Université Paris Descartes; APHP, Unité d'Hépatologie, Hôpital Cochin; INSERM U-1223 et USM20, Institut Pasteur, Paris, France; ⁶ Department of Internal Medicine-Digestive, Centre hospitalier universitaire Purpan, UMR 152 Toulouse 3 University, Toulouse; ⁷ Department of Hepatology, APHP, Hôpital Henri Mondor, Créteil; ⁸ Department of Hepatology, Hôpital Orléans, Orléans; ⁹ Department of internal medicine, Centre hospitalier universitaire Brest; ¹⁰ Department of Immunology, UF d'Immunochimie et d'autoimmunité, APHP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; ¹¹ Department of Hepatology, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris; ¹² Department of Biostatistics and Medical Data Processing; INSERM U717, Hôpital Saint-Louis, Paris, France.

Running title: Sofosbuvir plus daclatasvir in HCV-cryoglobulinemia vasculitis.

This paper includes: abstract 100 words, 998 words, 15 references, 1 table, 1 figure and 2 supplementary Tables and 2 supplementary Figures.

Correspondence should be addressed to: David Saadoun and Patrice Cacoub, AP-HP, Hôpital Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, 83 boulevard de l'hôpital. F-75013, Paris, France

Phone: + (33)(1) 42 17 80 09. Fax: + (33)(1) 42 17 80 33.

E Mail: david.saadoun@aphp.fr and patrice.cacoub@aphp.fr.

Disclosures

David Saadoun has received consulting and lecturing fees from Medimmune, Abbvie, Bristol myer squibb, Roche, Servier, Gilead, AstraZeneca and Glaxo Smith Kline. Si Nafa Si Ahmed received consulting and lecturing fees from Abbvie, Bristol Myers Squibb, Gilead, Janssen and Roche. Laurent Alric received consulting and lecturing fees from Gilead, Bristol Myers Squibb, Janssen, Abbvie, Merck Sharp Dohme, Roche. Christophe Hézode has been adviser and speaker for Abbvie, Bristol Myers Squibb, Gilead, Janssen, and Merck Sharp Dohme. Stanislas Pol, speaker: Glaxo Smith Kline, Bristol Myers Squibb, Boehringer Ingelheim, Janssen, Gilead, Roche, Merck Sharp Dohme, Sanofi, Novartis, Vertex, Abbvie; grants: Bristol Myers Squibb, Gilead, Roche, Merck Sharp Dohme; board member: Glaxo Smith Kline, Bristol Myers Squibb, Boehringer Ingelheim, Janssen, Gilead, Roche, Merck Sharp Dohme, Sanofi, Novartis, Vertex, and Abbvie. Thierry Poynard is the founder of BioPredictive marketing FibroTest (patent belong to Public Organization APHP). Patrice Cacoub has received consulting and lecturing fees from Abbvie, Astra Zeneca, Bristol-Myers Squibb, Gilead, Glaxo Smith Kline, Janssen, Merck Sharp Dohme, Roche, Servier and Vifor.

Download English Version:

<https://daneshyari.com/en/article/5658412>

Download Persian Version:

<https://daneshyari.com/article/5658412>

[Daneshyari.com](https://daneshyari.com)